Welcome to our dedicated page for Checkpoint Therapeutics news (Ticker: CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics stock.
Checkpoint Therapeutics, Inc., listed under the ticker CKPT, is a pioneering immuno-oncology biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Founded in 2014 and headquartered in New York, New York, the company operates as a subsidiary of Fortress Biotech, Inc.
Checkpoint Therapeutics focuses on developing non-chemotherapy, immune-enhanced combination treatments. One of its leading product candidates is CK-101, currently in phase I clinical trials, aimed at treating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Another significant candidate is Cosibelimab, a programmed death ligand-1 (PD-L1) inhibitor in phase I trials for selected recurrent or metastatic cancers.
In addition to these, Checkpoint Therapeutics is working on CK-103, a small molecule inhibitor targeting BET bromodomains, and CK-302, a human agonistic antibody designed for oncology indications. The company has also developed a strong portfolio of antibodies focusing on PD-L1, GITR, and CAIX targets.
Checkpoint Therapeutics collaborates with TG Therapeutics, Inc. to develop and commercialize specific assets in hematological malignancies. This partnership underscores the company's commitment to advancing cancer therapies through strategic alliances.
Checkpoint Therapeutics' robust pipeline, innovative approaches to cancer treatment, and strategic collaborations make it a significant player in the biopharmaceutical industry. Investors and stakeholders can look forward to the company's continuous advancements and contributions to oncology.
Checkpoint Therapeutics (Nasdaq: CKPT) has announced a registered direct offering of 1,700,000 shares of its common stock at a price of $3.60 per share, with expected gross proceeds of approximately $6.1 million. Concurrently, the company will issue Series A and Series B warrants to purchase up to 1,700,000 shares each, with an exercise price set at $3.35.
The offering is managed by H.C. Wainwright & Co., with closing anticipated on or about April 4, 2023. Proceeds are intended for working capital, general corporate purposes, and pre-commercial activities for cosibelimab, as Checkpoint awaits FDA review of its Biologics License Application for the drug.
FAQ
What is the current stock price of Checkpoint Therapeutics (CKPT)?
What is the market cap of Checkpoint Therapeutics (CKPT)?
What does Checkpoint Therapeutics, Inc. specialize in?
What are the key products in Checkpoint Therapeutics' pipeline?
Where is Checkpoint Therapeutics headquartered?
When was Checkpoint Therapeutics founded?
What strategic partnerships does Checkpoint Therapeutics have?
What is Cosibelimab?
What stage is CK-101 in?
Who is the parent company of Checkpoint Therapeutics?
What types of cancers is Checkpoint Therapeutics focusing on?
Does Checkpoint Therapeutics have any small molecule inhibitors in development?
